Skip to main content
ABSTRACT & COMMENTARY

Molnupiravir vs. Nirmatrelvir-Ritonavir for Early Symptomatic COVID-19

A randomized, controlled, multicenter Phase II clinical trial compared molnupiravir, ritonavir-boosted nirmatrelvir, or no drug for low-risk adult patients ages 18-50 years with symptomatic COVID-19. Viral clearance was 84% faster with ritonavir-boosted nirmatrelvir and 37% faster with molnupiravir compared to no treatment.